Roche begins phase 3 REMDACTA clinical trial in Covid-19 patients
Roche, in collaboration with Gilead Sciences, has initiated a phase 3 clinical study of Actemra/RoActemra plus investigational antiviral remdesivir, dubbed REMDACTA, in hospitalised patients with severe Covid-19 pneumonia.